Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr 1;106(4):1226-1227.
doi: 10.3324/haematol.2020.278203.

Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study."

Marco Picardi  1 , Claudia Giordano  2
Affiliations
Comment

Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study."

Marco Picardi et al. Haematologica. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN- 35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821. - PubMed
    1. Connors JM. Hodgkin lymphoma: outsmarting HRS cells. Blood. 2020;136(21):2362-2364. - PubMed
    1. Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica. 2020. Apr 9. [Epub ahead of print] doi:haematol.2019.243238. - PMC - PubMed
    1. Moskowitz AJ, Schröder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single- centre, phase 2 study. Lancet Oncol. 2015;16(3):284-292. - PubMed
    1. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40-48. - PMC - PubMed